all report title image

BIOCHIPS MARKET ANALYSIS

Biochips Market, By Product Type (DNA Chips, Protein Chips, Lab-on-chip Tissue Arrays, Cell Arrays), By End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Hospitals and Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Aug 2024
  • Code : CMI1146
  • Pages :152
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

Biochips Market Size and Trends

Global biochips market is estimated to be valued at USD 11.50 Bn in 2024 and is expected to reach USD 32.15 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 15.8% from 2024 to 2031.

Biochips Market Key Factors

To learn more about this report, request sample copy

Increasing application of biochips in the field of proteomics, genomics and drug discovery  can drive the market growth. Extensive R&D activities in the field of healthcare and growing demand for point-of-care testing and diagnostics can also boost demand for biochips during the forecast period. Advancements in microarray and microfluidic technologies can drive the global biochips market growth. Increasing government investments and funding for development of personalized medicine can drive the biochips market growth.

Increasing R&D Funding and Government Initiatives

Global biochips market  growth is driven by increasing funding for life science research and development across both public and private sectors. Governments around the world recognize the profound potential of biochip technology to revolutionize healthcare diagnosis and treatment, unlock new opportunities in personalized medicine, and drive national innovation and economic growth. Thus, there has been increase in funding for research into novel biochip applications from both federal grants and public-private partnerships. Major economies like the U.S., China, Japan, Germany and India have all outlined ambitious strategic plans designating bioengineering and bio microsystems as national priorities. Alongside increased R&D funding, governments are incentivizing commercialization through tax holidays, reimbursement programs, and seed grants for startups. Rising international collaborations can also pool resources and accelerate the pace of development.

Market Concentration and Competitive Landscape

Biochips Market Concentration By Players

Get actionable strategies to beat competition: Get instant access to report

Growing Demand for Point-of-Care Diagnostics

Rising global need for more accessible, affordable and rapid point-of-care testing can drive the market growth. Traditionally, diagnostic testing has been centralized in large clinical laboratories requiring samples to be shipped, sometimes over large distances, for analysis. This centralized model comes with disadvantages like delays in receiving results, high costs of infrastructure, and inability to conduct real-time or continuous monitoring applications. However, miniaturized biochip technologies are now making "mini clinical laboratories" a reality through portable and easy-to-use diagnostic devices. This decentralized, point-of-care approach provide benefits to healthcare providers and patients. It allows for timely clinical decisions, enrollment in early treatment programs, and management of chronic conditions outside of hospital settings. Such on-site, real-time diagnostic capabilities are becoming increasingly important as populations age and face a growing chronic disease burden. There has been huge demand for convenient, low-cost biochip-based tests for applications such as infectious disease screening, cancer screening, non-communicable disease monitoring and personal genome analysis. This rising requirement for point-of-care testing worldwide can offer opportunities for companies involved in developing biochip-powered diagnostic solutions.

Key Takeaways from Analyst

Global biochips market growth is driven by rising demand for personalized medicine and point-of-care diagnosis. Advancements in microfluidics and microarray technologies can enable development of novel biochips with high sensitivity and multiplex detection capabilities. This can address various applications across healthcare, food and environment testing. North America currently dominates the biochips market, owing to presence of major players and focus on R&D activities for disease diagnostics. However, Asia Pacific is likely to emerge as fastest growing region due to increasing healthcare expenditures and focus on precision medicine in countries like China and India.

Miniaturization of detection system and incorporation of multiple biochemical assays in a single chip offer immense opportunities, however, high development costs can pose challenges for startups in this space. Lack of standardization and compatibility issues between different platforms also slows down commercial adoption of novel biochips. Furthermore, inefficient distribution networks in developing nations can hamper  market growth. Strategic collaborations between players and regulatory bodies will be crucial to address these restraints. Strong government support for development of indigenous technologies will also boost emerging markets. Biochips market holds significant promise for innovations targeting point-of-care applications.

Market Challenges: High cost associated with biochip analysis

The high cost associated with biochip analysis can hamper the global biochips market growth. Biochip analysis requires expensive laboratory equipment, reagents and specialized research personnel, which makes the overall process quite costly. For example, initial set up and installation of a basic biochip analyzer can cost over US$ 100,000 and each experimental run on such equipment can be expensive. This heavy capital investment and operating expenses associated with biochip analysis makes it unaffordable for many small laboratories and research institutes especially in developing regions of the world. The high costs impose significant financial barriers and hurdles for widespread commercialization and clinical adoption of biochip technologies. Many diagnostic and genomic applications that could benefit from the high throughput analysis enabled by biochips are not viable due to the high per sample testing costs. Private healthcare providers are reluctant to invest in expensive biochip equipment as the return on investment may take significant time period. Patients also hesitate to opt for advanced but costly biochip diagnostics tests when equivalent options are available at lower prices through other conventional methods. Several startups and small biotech companies working on biochip-based solutions find it challenging to achieve economies of scale due to the high setup and operational expenses of initial prototyping.

Market Opportunities: Integration of biochips with microfluidics

The integration of biochips with microfluidics has the potential to significantly advance the global biochips market. Biochips combined with microfluidic technologies allow for complex biochemical reactions and analyses to be carried out in extremely small fluid volumes. This enables high-throughput molecular assays and analyses to be performed rapidly at the point-of-care. By miniaturizing full diagnostic labs onto a single chip sized device, microfluidic-biochip integration can make precision medicine more accessible and affordable worldwide. These lab-on-chip technologies could enable portable, easy-to-use, rapid and economic testing and screening for conditions like infectious diseases and chronic illnesses. Current research and development in this area aims to develop personalized disease screening, monitoring and drug response testing using saliva or blood samples of just microliters in volume. For instance, ongoing projects by NIH in 2021 are developing microfluidic-biochip devices capable of simultaneously detecting over fifty biomarkers from a single finger-prick of blood to comprehensively screen for heart disease and cancer risk. Such minimally invasive multi-analyte testing would prove transformative for healthcare especially in low-resource settings. It could facilitate widespread population-level screening campaigns and enable early detection when treatment options are most effective.

Biochips Market By Product Type

Discover high revenue pocket segments and roadmap to it: Get instant access to report

By Product Type- DNA Chips dominates due to wide range of applications

By product type, DNA chips segment is estimated to contribute the highest market share of 40% in 2024. DNA chips, also known as DNA microarrays, are a high-throughput screening technology that allows researchers to analyze a large number of target DNA sequences in parallel. DNA chips hold small DNA fragments called probes that complementarily bind to the target DNA or RNA sequences of interest. Using fluorescent tagging methods, researchers can analyze gene expression patterns or detect genetic mutations in thousands of samples simultaneously. The widespread use of DNA chips across genomics, genetic screening, and DNA/RNA analysis drives the segment growth in the global biochips market. DNA chips have revolutionized genome-wide association studies and enabled the discovery of genetic links to various diseases. Their ability to analyze hundreds or thousands of genes at once has accelerated genetic research and clinical diagnostics. DNA chips are extensively used in cancer research for tumor profiling, personalized therapy, and biomarker discovery. Their high sensitivity, precision, and throughput boosts their demand from biopharma companies and research organizations. The continuous technological advancements have further expanded applications of DNA chips. Developments like custom DNA microarrays have empowered researchers to design chips specific to their experiments. New DNA chips with higher probe densities and customized content allows for more in-depth investigations. Growing clinical requirements, such as non-invasive prenatal testing and pharmacogenomics, also boosts the need for innovative DNA chips.

By End User -Biotechnology and Pharmaceutical Companies dominates due to extensive R&D investments

By end user, biotechnology and pharmaceutical companies segment is estimated to contribute the highest market share of 35.12 % in 2024, primarily due to their massive investments in R&D. These organizations extensively utilize DNA chips, protein chips, and other biosensors for drug discovery, clinical trials, biomarker research, and toxicity screening. Biochips enable high-throughput screening of thousands of chemical compounds during lead identification stage of drug R&D. These facilitate analyzing interactions of drug candidates with targeted proteins, genes or cell receptors. This aids in accelerating early drug development with optimized candidates. In clinical research, biochips are widely used for pharmacogenomics to study individual variability in drug response and design more personalized therapies. Biopharma companies also invest heavily in developing customized biochips for proprietary use. For example, developing DNA or protein chips customized for biomarkers of certain disease areas like oncology. The generated results support clinical dossiers, companion diagnostic approvals and accelerate product commercialization. Biochips are gaining prominence in biomanufacturing for consistent quality control and testing during vaccine and biologics production.

Regional Insights

Biochips Market Regional Insights

To learn more about this report, request sample copy

North America dominates the global biochips market with an estimated market share of 41.3% in 2024. The region is home to several large multinational biochip companies and startup biochip developers. It has a significant presence across the entire value chain from biochip manufacturing to testing and research. Many major technological innovations in biochip design and development originate from research institutions and universities located in the U.S. and Canada.

The region also has a highly supportive regulatory environment and strong protection for intellectual property rights, which encourages continued investment in biochip R&D. Countries like the U.S. provide competitive public funding for biochip projects. This attracts more private funding and partnerships between industry and academia. Thus, North America captures the largest share of biochip sales globally. It exports biochips to emerging markets and imports certain specialty biochips from other regions.

Asia Pacific is poised to be the fastest growing regional market for biochips. Rising healthcare expenditures and increasing focus on personalized medicine boosts biochip adoption. Countries like China, Japan, South Korea and India are rapidly building their domestic biochip production capabilities. For example, China's government supports its biochip manufacturers through targeted incentives and subsidies. This  help reduce the region's reliance on biochip imports. Asia Pacific countries also provide attractive market opportunities due to their large and growing populations. Several multinational companies have established biochip manufacturing plants and R&D centers in Asia to cater to regional demand. Lower manufacturing costs compared to as North America and Europe allow Asia Pacific biochip makers to price their products competitively in the market. Continued expansion of the regional biohealthcare sector can drive the Asia Pacific biochips marketgrowth.

Market Report Scope

Biochips Market Report Coverage

Report Coverage Details
Base Year: 2023 Market Size in 2024: US$ 11.50 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 15.8% 2031 Value Projection: US$ 32.15 Bn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Product Type : DNA Chips (Cancer Diagnosis and Treatment, Gene Expression, SNP Genotyping, Genomics, Drug Discovery, Agricultural Biotechnology, Others), Protein Chips (Proteomics, Expression Profiling, Diagnostics, HTS, Others), Lab-on-chip  (IVD & POC, Others) Tissue Arrays, Cell Arrays 
  • By End User: Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Hospitals and Diagnostic Centers, Others 
Companies covered:

Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer, Inc., Fluidigm Corporation, Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Standard BioTools, GE Healthcare, F. Hoffmann-La Roche AG, QIAGEN, Randox Laboratories Ltd, LI-COR, Inc., Merck KGaA, Becton, Dickinson and Company, Arrayit Corporation, Nanostring Technologies, Inc., GnuBio, Inc.

Growth Drivers:
  • Increasing R&D Funding and Government Initiatives
  • Growing Demand for Point-of-Care Diagnostics
Restraints & Challenges:
  • High cost associated with biochip analysis
  • Lack of infrastructure in developing countries

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Biochips Industry News

  • In May 2024, Visionary Holdings Inc., a leading private education provider specializing in artificial intelligence and life sciences, announced its collaboration with Canada’s B. Braun Biochip Technology Group to form Visionary Biotechnology Group Co., Ltd. in Toronto. This collaboration is expected to significantly influence both economic and social value, enhancing Visionary Group's global impact in biotechnology. It presents notable value for investors in the short, medium, and long term.
  • In October 2022, MicrobioSeq (CD Genomics) introduced Phage Whole-Genome Sequencing to aid in the discovery of biomarkers and the development of non-antibiotic treatment methods. Utilizing next-generation sequencing and long-read sequencing technologies, including Illumina HiSeq, Nanopore, and PacBio SMRT sequencing, CD Genomics offers virus/phage sequencing services and supports in-depth research in structural and comparative genomics.
  • In October 2022, Thermo Fisher Scientific Inc. enhanced its Applied Biosystems Chromosome Analysis Suite (ChAS) software through a partnership with Genoox, a company specializing in community-driven genomic data. This upgrade enables ChAS users to access Genoox’s cloud-based AI platform. With the integration of Franklin, the software now offers an automated and flexible workflow for immediate, consistent, and reproducible cytogenetic analysis results.

*Definition: Global biochips market consists of microarrays or microchips that can detect and measure thousands of biological molecules or biological reactions simultaneously. This market involves the manufacture and sale of biochips/microarrays used for research in fields like genomics, proteomics, drug discovery, disease diagnostics, and other life science applications. The biochips analyze chemical reactions on a solid surface and help study biological systems in depth at the molecular level enabling advances in healthcare and biotechnology.

Market Segmentation

 Product Type Insights (Revenue, USD Bn, 2019 - 2031)

  • DNA Chips
    • Cancer Diagnosis and Treatment
    • Gene Expression
    • SNP Genotyping
    • Genomics
    • Drug Discovery
    • Agricultural Biotechnology
    • Others
  • Protein Chips
    • Proteomics
    • Expression Profiling
    • Diagnostics
    • HTS
    • Others
  • Lab-on-chip
    • IVD & POC
    • Others
  • Tissue Arrays
  • Cell Arrays
  •  End User Insights (Revenue, USD Bn, 2019 - 2031)
    • Biotechnology and Pharmaceutical Companies
    • Academic & Research Institutes
    • Hospitals and Diagnostic Centers
    • Others
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Inspire Medical Systems, Inc.
    • LinguaFlex
    • LivaNova PLC
    • Medtronic
    • Siesta Medical Inc.
    • Koninklijke Philips N.V.
    • Nihon Kohden Corporation
    • Nyxoah SA
    • ResMed
    • Fisher & Paykel Healthcare Limited
    • SomnoMed
    • VYAIRE
    • Drive DeVilbiss International
    • Somnowell
    • Natus Medical Incorporated
    • CONTEC MEDICAL SYSTEMS CO., LTD
    • CLEVELAND MEDICAL DEVICES INC.
    • Nox Medical
    • Advanced Brain Monitoring, Inc.

Share

About Author

Abhijeet Kale

Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.

Missing comfort of reading report in your local language? Find your preferred language :

Frequently Asked Questions

The global Biochips Market size is estimated to be valued at USD 11.50 billion in 2024 and is expected to reach USD 32.15 billion in 2031.

The CAGR of global biochips market is projected to be 15.8% from 2024 to 2031.

Increasing R&D funding and government initiatives and growing demand for point-of-care diagnostics are the major factors driving the growth of global biochips market.

High cost associated with biochip analysis and lack of infrastructure in developing countries are the major factors hampering the growth of global biochips market.

In terms of product type, DNA chips segment is estimated to dominate the market in 2024.

Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer, Inc., Fluidigm Corporation, Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Standard BioTools, GE Healthcare, F. Hoffmann-La Roche AG, QIAGEN, Randox Laboratories Ltd, LI-COR, Inc., Merck KGaA, Becton, Dickinson and Company, Arrayit Corporation, Nanostring Technologies, Inc., GnuBio, Inc.

North America is expected to lead the global biochips market.
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type





Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.